home > News and Publications > Publications
J & J COVID-19 Vaccine: CDC Releases Alert Geared for Health Professionals
Posted on: 4/16/2021
blood clot

Earlier this week the Centers for Disease Control and Prevention (CDC) issued a Health Alert with specific recommendations for healthcare professionals pertaining to the Johnson & Johnson (Janssen) COVID-19 vaccine. 

The alert comes on the heels of a recommendation from the CDC and Food and Drug Administration (FDA) to pause the use of the Johnson & Johnson COVID-19 vaccine to ensure that the healthcare community is aware of the potential for adverse events, including rare blood clotting (cerebral venous sinus thrombosis in combination with low levels of blood platelets [thrombocytopenia]). In addition, the alert emphasizes that this type of blood clot requires unique treatment

The CDC’s Advisory Committee on Immunization Practices (ACIP) met in an emergency meeting on Wednesday to discuss the pause, and decided to delay a decision on whether to resume use of the Johnson & Johnson vaccine until it had more data on the risks, cause, and frequency of the blood clot condition. It will meet again to consider the data and make a decision within a week and a half.

Watch the AMA’s webinar COVID-19: What Physicians Need to Know with Peter Marks, MD, PhD, Director of the Center for Biologics Evaluation and Research at the FDA. The webinar focuses on the Johnson & Johnson (Janssen) vaccine.  

If you have questions, please contact the ISMS Health Policy Research and Advocacy team  by email

View Full Site View Mobile Site